Led by Isaac Harris at the Wilmot Cancer Institute, researchers analyzed breast tumor samples and preclinical models, confirming tumors aggressively consume glutathione and that blocking its use slows tumor growth.
The study, published in Nature, identified an existing drug that restricts tumor access to glutathione, with ongoing efforts to improve this therapy and explore drug-diet combinations for better cancer outcomes.
Researchers caution against high-dose glutathione supplements, noting cancer cells can hijack antioxidants, and emphasize the importance of balanced diets while pursuing novel therapies that target tumor metabolism without harming healthy cells.
Could a drug that starves tumors of glutathione become a major new cancer therapy?
With a drug already found, how soon could this cancer-starving approach reach human trials?
How do cancer cells hijack a protective antioxidant for their own aggressive growth?
If antioxidants can fuel cancer, should we rethink our daily vitamins and supplements?
Why are antioxidants from food safe when high-dose supplements might be dangerous?